Clinical TrialApr 14, 2026, 08:47 AM
Actuate's Elraglusib Boosts Pancreatic Cancer Survival by >40%
AI Summary
Actuate Therapeutics announced the publication of positive Phase 2 clinical trial data for elraglusib in combination with chemotherapy for previously untreated metastatic pancreatic cancer. The study, published in Nature Medicine, showed a significant increase in median overall survival by over 40% and doubled the one-year survival rate to 44% compared to standard chemotherapy alone. This data reinforces elraglusib's potential as a first-line therapy for a difficult-to-treat cancer, with an acceptable safety profile, and the company plans further research into synergistic combinations.
Key Highlights
- Median overall survival increased by >40% with elraglusib.
- One-year survival rate doubled to 44% vs. 22% in control arm.
- Elraglusib reduced the risk of death by 38% (HR 0.62).
- Median overall survival reached 10.1 months vs. 7.2 months.
- 18-month survival rate >20% in elraglusib arm vs. 4% in control.